Journals / Eurasian Journal of Medicine / 2009 / Cilt: 41 - Sayı: 1

Lasidipin, ramipril ve valsartanın sıçanlarda isoprotrenol ile uyarılan miyokard infarktüsü sonrası akut ve kronik periyotta serum BNP seviyeleri üzerine etkileri

Effects of lacidipine, ramipril and valsartan on serum BNP levels in acute and chronic periods following isoproterenol-induced myocardial infarction in rats

Pages
44–49
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, both RAM and VAL may become first-line drugs for the treatment of hypertensive patients who are at high risk for cardiovascular failure.TopAbstractIntroductionMethodsResultsDisscussion

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Myocardial infarction (MI) as a result of cardiovascular disease is the principal cause of death in both developed and developing countries.
📊
Key Findings & Data:Serum BNP was found to be significantly increased in the acute MI model, but not in the chronic MI model.
💡
Conclusion & Impact:Therefore, both RAM and VAL may become first-line drugs for the treatment of hypertensive patients who are at high risk for cardiovascular failure.TopAbstractIntroductionMethodsResultsDisscussion
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective. Myocardial infarction (MI) as a result of cardiovascular disease is the principal cause of death in both developed and developing countries. Brain natriuretic peptide (BNP) is an important marker of cardiac failure. Cardioprotective activities of the antihypertensive drugs lacidipine (LAC), ramipril (RAM) and valsartan (VAL), against isoproterenol (ISO)-induced MI, have been determined. However, the levels of BNP, an indicator of left ventricular failure, have not been evaluated. Materials and Methods. This study investigated the effects of LAC, RAM and VAL on serum BNP levels in acute and chronic periods after ISO-induced MI in rats.Results. Serum BNP was found to be significantly increased in the acute MI model, but not in the chronic MI model. RAM and VAL application decreased BNP levels that had been increased after acute MI induction. Additionally, no significant differences were seen in chronic MI+drug groups compared with both intact and chronically infarcted control groups.Conclusion. The acute MI model, but not the chronic MI model, was associated with increased serum BNP levels. Pretreatment with RAM and VAL, but not LAC, prevented the acute MI-induced increase in serum BNP levels, suggesting that inhibition of the renin-angiotensin system has prophylactic effects in the acute MI model. Therefore, both RAM and VAL may become first-line drugs for the treatment of hypertensive patients who are at high risk for cardiovascular failure.TopAbstractIntroductionMethodsResultsDisscussion

Özet

Amaç. Miyokard infarktüsü (Mİ) hem gelişmiş hem de gelişmekte olan ülkelerde kardiyovasküler hastalıklar sonucu oluşan ölümün esas sebebidir. Brain natriuretic peptide (BNP) kardiyak hasarın önemli bir göstergesidir. Antihipertansif ilaçlar olan lasidipin (LAC), ramipril (RAM) ve valsartanın, izoproterenol (ISO) ile indüklenen Mİ üzerinde, koruyucu etkileri belirlenmiştir. Ancak sol ventrikül hasarının bir göstergesi olan BNP seviyeleri değerlendirilmemiştir. Gereç ve Yöntem. Bu çalışmada LAC, RAM ve VAL'ın serum BNP seviyeleri üzerine olan etkileri sıçanlarda ISO ile indüklenen MI'da akut ve kronik periyot da incelenmiştir.Bulgular. Serum BNP seviyeleri akut MI modelinde artarken, kronik MI modelinde artmamıştır. RAM ve VAL uygulamasının, sıçanlarda ISO uygulamasıyla oluşan, akut MI'dan sonra artmış olan BNP seviyelerini anlamlı şekilde azalttığı belirlenmiştir. Kronik MI+ ilaç gruplarında da intakt ve kronik MI'lı kontrol grupları ile karşılaştırıldığında anlamlı bir değişiklik saptanmamıştır.Sonuç. Serum BNP seviyelerinin, akut MI modelinde artırdığı, ancak kronik MI modelinde artmadığı bulunmuştur. RAM ve VAL ile yapılan ön tedavinin, serum BNP seviyesinde MI'la indüklenen artışı önlemesi, ancak LAC'ın önleyememesi, reninanjiotensin sisteminin inhibisyonunun akut MI modelinde pro- filaktik etkileri olduğunu göstermektedir. Bizim bulgularımız gösterdi ki, RAM ve VAL kardiyovasküler yetmezlik riski yüksek olan hipertansiyon hastalarında ilk tercih edilecek ilaçlar haline gelebilir.

🔖

Cite This Article

BAYIR, Y., HALICI, Z., SÜLEYMAN, H., KELEŞ, M. S., ÇADIRCI, E. (2022). Lasidipin, ramipril ve valsartanın sıçanlarda isoprotrenol ile uyarılan miyokard infarktüsü sonrası akut ve kronik periyotta serum BNP seviyeleri üzerine etkileri. Eurasian Journal of Medicine, Cilt: 41 - Sayı: 1, 44–49. https://ajindex.com/articles/509358

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Maxwell SR, Lip GY. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol 1997;58: 95–117
  2. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol 1997; 47: 287–96
  3. Wexler BC, Greenberg BP. Protective effects of clofibrate on ısoproterenol-ınduced myocardial-ınfarction in arteriosclerotic and non-arteriosclerotic rats. Atherosclerosis 1978;29:373–95
  4. Yeager JC, Iams SG. The hemodynamics of isoproterenol-induced cardiac failure in the rat. Circ Shock 1981; 8:151–63
  5. Bloom S, Davis Dl. Calcium as mediator of isoproterenol- induced myocardial necrosis. Am J Pathol 1972;69:459–70
  6. Fleckenstein A, Janke J, Döring HJ, Leder O. Myocardial fiber necrosis due to intracellular Ca overload-a new principle in cardiac pathophysiology. Recent Adv Stud Cardiac Struct Metab 1974;4:563–80
  7. Sharma M, Kishore K, Gupta SK, Joshi S, Arya DS. Cardioprotective potential of ocimum sanctum in isoproterenol induced myocardial infarction in rats. Mol Cell Biochem 2001; 225:75–83
  8. Mazzone M, Forte P, Portale G et al. Brain natriuretic peptide and acute coronary syndrome. Minerva Med 2005;96:11-8
  9. Rademaker MT, Richards AM. Cardiac natriuretic peptides for cardiac health. Clin Sci 2005; 108: 23–36
  10. Campbell DJ, Mitchelhill KI, Schlicht SM, Booth RJ. Plasma aminoterminal pro-brain natriuretic peptide: A novel approach to the diagnosis of cardiac dysfunction. J Card Fail 2000; 6: 130–9
  11. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic review. BMJ 2005; 330: 625
  12. Jourdain P, Jondeau G, Funck F et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARSBNP Multicenter Study. J Am Coll Cardiol 2007; 49: 1733– 9
  13. Bayir Y. Sıçanlarda isoprotrenol ile oluşturulan miyokard infarktüsü modelinde dNA hasarı ve oksidatif stres üzerine lasidipin, ramipril ve valsartan'nın etkilerinin incelenmesi. Doktora tezi. Atatürk Üniversitesi, Sağlık Bilimleri Enstitüsü, Tıp Fakültesi, Biyokimya. 2009
  14. Kyselovic J, Krenek P, Wibo M, Godfraind T. Effects of amlodipine and lacidipine on cardiac remodelling and renin production in saltloaded stroke-prone hypertensive rats. Br J Pharmacol 2001;134: 1516–22
  15. Wölkart